Tiny implanted device delivers drugs to sarcoma tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests an implantable device placed during planned surgery to deliver cancer medicines directly to sarcoma tumors and study how they affect the tumors. It may be an option if your sarcoma has come back or spread and surgery is part of standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sarcoma that has come back or spread, confirmed by a biopsy
- Your care team recommends surgery to remove tumor(s) as standard treatment
- You are at least 10 years old
- You can sign informed consent to join the study
- Your general ability to function is fair (ECOG score 0–2)
- You can safely receive the specific drug(s) in the implant (no allergy or prior serious reaction)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests a combination of two drugs—gemcitabine (a chemotherapy drug) and nab-sirolimus (a targeted therapy)—for people with advanced soft-tissue sarcoma or leiomyosarcoma, especially those whose tumors have a specific genetic change in the TSC2 or TSC1 genes. The goal is to see if this combination can shrink tumors or slow their growth.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial tests a new light-based drug delivery system to treat sarcomas. It looks at how well this platform works during surgery or biopsy for patients with soft tissue or bone sarcomas.
Hear when a new Metastatic Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.